Razi Vaccine & Serum Research Institute as the first manufacturer of antivenom immunoglobulin products in the Middle East is actively participating in this workshop to understand how the risk-benefit assessment process can help to improve RVSRI’s production of life-saving products and to identify common deficiencies that arise and correct them through better self-inspection practices.

 As snakebite envenoming continues to pose a serious public health challenge in these regions, the workshop will convene regulators, procurement agencies, and manufacturers to address critical issues surrounding the assessment process for snake antivenom products. The initiative aligns with the World Health Assembly resolution WHA71.5, underscoring the WHO's commitment to ensuring the quality of antivenoms—a commitment that this workshop seeks to advance.

As mentioned by WHO, the purpose of the meeting is to provide regulators, procurement agencies and the manufacturers of snake antivenom immunoglobulin products with information about the WHO risk-benefit assessment of snake antivenoms.  

The main objective of this technical meeting will be to discuss a range of issues related to the assessment process, including application procedures, the work performed, and the outcomes that the process generates. The meeting will better equip regulators and procurement agencies to interpret the findings of the assessments and make use of these in their work.

This workshop represents a crucial opportunity for collaboration and knowledge sharing among stakeholders committed to enhancing snake antivenom products. By working together, the participants aim to improve public health outcomes and ensure that effective treatments are readily available for those affected by snakebite envenoming.